Incentives and disincentives to participate in prophylactic vaccine studies.

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Incentives and disincentives to participate in prophylactic vaccine studies.

Int Conf AIDS. 1993 Jun 6-11;9(1):101 (abstract no. WS-C20-3). Unique Identifier : AIDSLINE MED/93333229
Virochsiri K; Temoshok LR; Nitayaphan S; Sukhawarn C; Chinaworapong S; Carr J; Royal Thai Army Medical Department, Bangkok.

Abstract: OBJECTIVES: In preparation for expected testing of prophylactic HIV vaccines, it is critical to understand whether and why different potential communities might want to participate in such trials, and the anticipated "behavioral side effects" of participation. METHODS: A questionnaire to assess possible health-related, social, and psychological incentives and disincentives to participate in a Phase I prophylactic vaccine study in Thailand was administered to 300 health care providers in Bangkok. RESULTS: Preliminary analyses on 124 health care workers indicated concerns in 54% about short-term side effects of injections; however, only 11% believed there would be any toxic long-term effects. Subjects believed there would be problems that could preclude their volunteering if HIV antibody screening were done on vaccine volunteers when applying for a job 45%), for health insurance (48%), or for hospitalization (33%). In terms of incentives to participate, 20% believed the vaccine might prevent HIV infection in volunteers, while 60% were "not sure". CONCLUSIONS: Public presentations to recruit volunteers for vaccine studies must be carefully balanced to promote accurate understanding of the study's safety, as well as the limitations of information about the vaccine's efficacy. At the same time, the needs and concerns of groups or communities from which vaccine trial volunteers would be recruited must first be assessed and then addressed.

Keywords: *AIDS Vaccines/TOXICITY *Health Personnel *Motivation
931130
M93B5818

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .